Study objective: To investigate the prognostic
significance of interleukin (IL)-10 serum levels in advanced non-small
cell lung cancer (NSCLC) patients.
Design: IL-10 serum
levels were measured before chemotherapy, on completion of therapy, and
at follow-up by means of a commercially available enzyme-linked
immunoassay. The results were then analyzed in comparison with other
prognostic variables, and a model predicting overall survival (OS) and
time to treatment failure (TTF) was finally generated.
Setting: University hospital.
Sixty consecutive patients with TNM stage III or IV NSCLC undergoing
conventional platinum-based regimens.
Elevated levels of serum IL-10 were found in cancer patients with
respect to healthy control subjects (17.7 ± 4.4 vs 9.2 ± 1.5
pg/mL, respectively; p < 0.05), with patients with metastatic
disease showing significantly higher levels than patients with
undisseminated cancer (21.0 ± 4.2 vs 14.3 ± 1.2 pg/mL,
respectively; p < 0.05). Following completion of treatment, patients
were classified as responders if they had achieved either one of the
following: complete response, partial response, or stable disease; and
nonresponders, in case of progressive disease. Retrospective analysis
of basal IL-10 serum levels in these two subgroups showed a significant
difference between responders and nonresponders (15.2 ± 2.2 vs
21.4 ± 4.2 pg/mL, respectively; p < 0.05). Moreover, a further
significant increase in IL-10 serum levels was observed in
nonresponders at the end of therapy (21.4 ± 4.2 vs 26.0 ± 4.3
pg/mL, prechemotherapy and postchemotherapy, respectively;
p < 0.05), whereas values in responders were found to have
significantly decreased (15.2 ± 2.2 vs 14.8 ± 2.2 pg/mL,
prechemotherapy and postchemotherapy, respectively; p < 0.05). Using
univariate and multivariate analyses, both OS and TTF were shown to be
affected by the mean pathologic levels of IL-10. Stepwise regression
analysis identified IL-10 serum level and stage as the prognostic
factors related to OS, and IL-10 serum level and performance status as
the prognostic factors related to TTF.
conclusion, this study shows that the measurement of pretreatment IL-10
serum levels is of independent prognostic utility in patients with
NSCLC and may be useful for detection of disease